AmoyDx® Pan Lung Cancer PCR Panel
Approved in Japan as a Companion Diagnosticfor selpercatinib RET fusion positive NSCLCTOKYO and XIAMEN, March 27th, 2023 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd.,(“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that theJapanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan LungCancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive
non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg and 80 mg .
The AmoyDx® PLC Panel is based on polymerase chain reaction (PCR) technology and cansimultaneously evaluate the presence of activation alterations in 11 driver genes (EGFR/ ALK/ROS1/ KRAS/ BRAF/ HER2/ RET/ MET/ NTRK1/ NTRK2/ NTRK3 genes) when all genes on the panel
are approved as companion diagnostics. The AmoyDx® PLC Panel has received approval for theidentification of activating alterations in seven driver genes (EGFR, ALK, ROS1, BRAF, MET exon 14
skipping, KRAS, and RET) for twelve (12) associated targeted therapies in NSCLC. With its highsensitivity and short turnaround time, the AmoyDx® PLC Panel is expected to be an important
clinical diagnostic in guiding treatment opportunities for NSCLC patients.
“With this approval, the AmoyDx® PLC Panel can now be used to identify RET fusion-positive
NSCLC patients for treatment with selpercatinib, thereby expanding their therapeutic options.
We look forward to developing and commercializing additional, new therapy options for Japanesepatients,” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis, Li-MouZheng, Ph.D., Founder and Chief Executive Officer of AmoyDx and Wenn Sun, Ph.D., Founder andPresident of PREMIA.

About AmoyDx PLC Panel:(1) Product nameAmoyDx® Pan Lung Cancer PCR Panel(2) Approval No.
(3) Purpose of use

30300EZX00069000(4) Testing method(5) Sample(6) Package size(7) Marketing
Authorization Holder(8) Manufacturer

Detection of EGFR gene mutations, ALK fusion gene, ROS1 fusion gene,
BRAF gene mutations, MET exon 14 skipping mutation, KRAS genemutations and RET fusion genes in nucleic acids extracted from cancertissue
Used as an adjunct to determine the indications of the following nine
antineoplastic agents for patients with NSCLC.
・EGFR gene mutation
Gefitinib, Erlotinib hydrochloride, Afatinib maleate,
Osimertinib mesylate
・ALK fusion gene
Crizotinib, Alectinib hydrochloride, and Brigatinib
・ROS1 fusion gene
Crizotinib
・BRAF V600E mutation
Combined administration of Dabrafenib mesylate and Trametinib
dimethyl sulfoxide
・MET exon 14 skipping mutation
Tepotinib
・KRAS G12C mutation
Sotorasib
・RET fusion gene
Selpercatinib
Real-time PCR
FFPE tissue and fresh frozen tissue in which the presence of tumor
cells was confirmed
12 tests / kit
Riken Genesis Co., Ltd.
Amoy Diagnostics Co., Ltd.

About Riken Genesis Co., Ltd.
RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic
testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience inthe field of personalized medicine. The company provides highly reliable tests based on international
quality standards, as demonstrated by its CLIA certification, being the first organization in Japan tomeet this U.S. quality control standard for clinical laboratories. For more information, please visit
www. rikengenesis.jp
About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)
Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of moleculardiagnostics for precision oncology, focusing on companion diagnostics product development andcommercialization. A rich product portfolio has been established with more than 20 products
approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in morethan 60 countries are benefiting from AmoyDx products. With multiple technological platforms
and full capability for companion diagnostics product development and commercialization,
AmoyDx has become an important diagnostics partner of many pharmaceutical companies overthe globe. For more information, please visit www.amoydiagnostics.com.
About Precision Medicine Asia (PREMIA)PREMIA offer an integrated platform for the development of innovative oncology therapies anddiagnostics in Asia, the fastest growing market for the pharmaceutical industry. PREMIA also
manages a clinical-genomic lung cancer registry, the largest in the region, which includes morethan 19,000 patients and allows an efficient patient identification process for clinical trial
enrollment through participation by more than 200 hospitals in Japan, Taiwan, Malaysia andThailand. For more information, please visit www.premia-inc.com

Contacts:
Yuko Oi
General Manager, Marketing department
Tel: +81-3-5759-6042
yuko.oi@rikengenesis.jp

Paul Huang
Director, International business
Tel: + 86-592-6806058
paulhuang@amoydx.com

Vivian Liu
Director, Corporate Operation
Tel: 852-3978-2288
vliu@premia-inc.com